Details of the Drug

General Information of Drug (ID: DMIBFVF)

• Drug Name: Nirsevimab

Indication

Disease Entry	ICD 11	Status	REF
Lower respiratory tract infection	CA45	Approved	[1]
Respiratory syncytial virus infection	1C80	Phase 2	[2]

• Affected Organisms: Humans and other mammals
• ATC Code:
  J06BD08: Nirsevimab
  J06BD: Antiviral monoclonal antibodies
  J06B: IMMUNOGLOBULINS
  J06: IMMUNE SERA AND IMMUNOGLOBULINS
  J: ANTIINFECTIVES FOR SYSTEMIC USE
• Drug Type: Antibody
• Cross-matching ID:
  UNII: VRN8S9CW5V
  DrugBank ID: DB16258
  TTD ID: DNF95E
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761328
• [2] ClinicalTrials.gov (NCT04484935) Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children. U.S. National Institutes of Health.